Darbepoetin alfa


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV/SC Anaemia of chronic renal failure Initial: 0.45 mcg/kg SC/IV once weekly. Alternatively, 0.75 mcg/kg every 2 weeks or 1.5 mcg/kg once monthly via SC inj in patients not on dialysis. Adjust dose according to response at intervals of at least 4-wk. SC Anaemia in chemotherapy patients Initial: 500 mcg once every 3 weeks. Alternatively, 2.25 mcg/kg once weekly. Discontinue therapy approx 4 weeks after the end of chemotherapy.
Dosage Details
Parenteral
Anaemia of chronic renal failure
Adult: Initially, 0.45 mcg/kg SC/IV once weekly. Alternatively, 0.75 mcg/kg every 2 weeks or 1.5 mcg/kg once monthly via SC inj in patients not on dialysis. Dose may be increased or decreased by 25% once every 4 weeks, according to Hb level. Maintenace dose: 0.45 mcg/kg SC/IV once weekly or once every 2 weeks. Titrate dose to maintain target Hb level.
Child: Same as adult dose.

Subcutaneous
Anaemia in chemotherapy patients
Adult: Initially, 500 mcg once every 3 weeks. Alternatively, 2.25 mcg/kg once weekly. Dose reduction up to 50%, dosing interruption, or discontinuation may be required according to Hb level (refer to detailed product guideline). Discontinue therapy approx 4 weeks after the end of chemotherapy.
Contraindications
Hypersensitivity, uncontrolled hypertension.
Special Precautions
Pregnancy and lactation, children. Hypertension; history of seizures; hepatic impairment; sickle cell anaemia; sudden stabing migraine-like pain (warning sign of hypotensive crisis); exclude other causes of anaemia; ischaemic vascular disease; thrombocytosis; epilepsy; malignant disease; increase in heparin dose may be needed; increased risk of thrombosis when used for anaemia before orthopedic surgery; CV disease including recent MI/cerebrovascular accident. Monitor haemoglobin, BP and electrolytes; platelet count for 1st 8 wk.
Adverse Reactions
Hypertension, hypotension, chest pain, fatigue, fever, headache, dizziness, GI effects; myalgia, arthralgia, limb pain; skin reactions; shunt reactions, hyperkalaemia; dyspnea, cough, bronchitis; infection; transient increase in platelet count; influenza-like symptoms; peripheral oedema; Inj site pain.
IV/Parenteral/SC: C
Overdosage
No overdosage symptoms reported so far as it has wide therapeutic margin. In the event of polycythaemia, treatment may be temporarily withheld. Phlebotomy may be performed if clinically indicated.
Drug Interactions
Antagonism of hypotensive effect and increased risk of hyperkalemia with ACE inhibitors and angiotensin II receptor antagonists. Ethanol.
Action
Description: Darbepoetin alfa is a biosynthetic form of erythropoietin. It stimulates the division and differentiation of erythroid progenitor cells; reticulocytes are released from the bone marrow and matures into erythrocytes thereby regulating erythropoiesis.
Pharmacokinetics:
Absorption: IM admin: Slow absorption and bioavailability is about 37%.
Excretion: Terminal half-lives: 21 hr (IV admin) and 49 hr (SC admin).
Storage
Store at 2-8°C.
Disclaimer: This information is independently developed by MIMS based on Darbepoetin alfa from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in